Selenium compounds inhibit IκB kinase (IKK) and nuclear factor-κB (NF-κB) in prostate cancer cells

Molecular Cancer Therapeutics

Volumn 1, Issue 12, 2002, Pages 1079-1087

  Gasparian, Alexander V ^a   Yao, Ya Juan ^a   Lü, Junxuan ^a   Yemelyanov, Alexander Y ^a   Lyakh, Lyudmila A ^b   Slaga, Thomas J ^a   Budunova, Irina V ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHUK PROTEIN, HUMAN; ENZYME INHIBITOR; I KAPPA B KINASE; IKBKB PROTEIN, HUMAN; IKBKE PROTEIN, HUMAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; METHYLSELENIC ACID; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; ORGANOSELENIUM DERIVATIVE; PROTEIN SERINE THREONINE KINASE; SELENIUM;

ACTIVE TRANSPORT; ADENOVIRUS; APOPTOSIS; ARTICLE; CELL CULTURE; CELL NUCLEUS; CYTOSOL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; HUMAN; MALE; METABOLISM; PROSTATE TUMOR; PROTEIN BINDING; TIME; WESTERN BLOTTING;

ACTIVE TRANSPORT, CELL NUCLEUS; ADENOVIRIDAE; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL NUCLEUS; CYTOSOL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; I-KAPPA B KINASE; LUCIFERASES; MALE; NF-KAPPA B; ORGANOSELENIUM COMPOUNDS; POLY(ADP-RIBOSE) POLYMERASES; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; SELENIUM; TIME FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0043157958     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Ganther, H. E. Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase. Carcinogenesis (Lond.), 20: 1657-1666, 1999. (Pubitemid 29410542)
2. Ip, C. Lessons from basic research in selenium and cancer prevention. J. Nutr., 128: 1845-1854, 1998. (Pubitemid 28509845)
3. Clark, L. C., Combs, G. F., Jr., Turnbull, B. W., Slate, E. H., Chalker, D. K., Chow, J., Davis, L. S., Glover, R. A., Graham, G. F., Gross, E. G., Krongrad, A., Lesher, J. L., Jr., Park, H. K., Sanders, B. B., Jr., Smith, C. L., and Taylor, J. R. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA, 276: 1957-1963, 1996. (Pubitemid 26427723)
4. Clark, L. C., Dalkin, B., Krongrad, A., Combs, G. F., Jr., Turnbull, B. W., Slate, E. H., Witherington, R., Herlong, J. H., Janosko, E., Carpenter, D., Borosso, C., Falk, S., and Rounder, J. Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br J. Urol., 81: 730-734, 1998. (Pubitemid 28316638)
5. Schrauzer, G. N. Anticarcinogenic effects of selenium. Cell Mol. Life Sci., 57: 1864-1873, 2000. (Pubitemid 32102582)
6. Yu, S. Y., Zhu, Y. J., and Li, W. G. Protective role of selenium against hepatitis B virus and primary liver cancer in Qidong. Biol. Trace Elem. Res., 56: 117-124, 1997. (Pubitemid 27198254)
7. Zheng, W., Blot, W. J., Diamond, E. L., Norkus, E. P., Spate, V., Morris, J. S., and Comstock, G. W. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Res., 53: 795-798, 1993. (Pubitemid 23077864)
8. Dalkin, B. W., Lilico, A. J., Reid, M. E., Jacobs, E. T., Combs, J. F., Slate, E. H., Turnbull, B. W., and Marshall, J. R. Selenium and chemoprevention against prostate cancer. hormone. Proc. Am. Assoc. Cancer Res., 42: 460, 2001.
9. Combs, G. F., Jr., and Gray, W. P. Chemopreventive agents: selenium. Pharmacol. Ther., 79: 179-192, 1998. (Pubitemid 28393874)
10. Raich, P. C., Lu, J., Thompson, H. J., and Combs, G. F., Jr. Selenium in cancer prevention: clinical issues and implications. Cancer Investig., 19: 540-553, 2001. (Pubitemid 32619393)
11. Jiang, C., Ganther, H., and Lu, J. Monomethyl selenium-specific inhibition of MMP-2 and VEGF expression: implications for angiogenic switch regulation. Mol. Carcinog., 29: 236-250, 2000. (Pubitemid 32052668)
12. Jiang, C., Wang, Z., Ganther, H., and Lu, J. Caspases as key executors of methyl selenium-induced apoptosis (anoikis) of DU-145 prostate cancer cells. Cancer Res., 61: 3062-3070, 2001. (Pubitemid 32691955)
13. Ip, C., Thompson, H. J., Zhu, Z., and Ganther, H. E. In vitro and in vivo studies of methylseleninic acid: evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res., 60: 2882-2886, 2000. (Pubitemid 30395810)
14. Berges, R. R., Vukanovic, J., Epstein, J. I., CarMichel, M., Cisek, L., Johnson, D. E., Veltri, R. W., Walsh, P. C., and Isaacs, J. T. Implication of cell kinetic changes during the progression of human prostatic cancer. Clin. Cancer Res., 1: 473-480, 1995.
15. Baldwin, A. S., Jr. The NF-κB and IκB proteins: new discoveries and insights. Annu. Rev. Immunol., 14: 649-683, 1996.
16. Verma, I. M., Stevenson, J. K., Schwarz, E. M., Van Antwerp, D., and Miyamoto, S. Rel/NF-κB/IκB family: intimate tales of association and dissociation. Genes Dev., 9: 2723-2735, 1995. (Pubitemid 3009952)
17. Whiteside, S. T., and Israel, A. IκB proteins: structure, function and regulation. Semin. Cancer Biol., 8: 75-82, 1997.
18. Chen, Z., Hagler, J., Palombella, V. J., Melandri, F., Scherer, D., Ballard, D., and Maniatis, T. Signal-induced site-specific phosphorylation targets IκBα to the ubiquitin-proteasome pathway. Genes Dev., 9: 1586-1597, 1995.
19. DiDonato, J., Mercurio, F., Rosette, C., Wu-Li, J., Suyang, H., Ghosh, S., and Karin, M. Mapping of the inducible IκB phosphorylation sites that signal its ubiquitination and degradation. Mol. Cell. Biol., 16: 1295-1304, 1996.
20. Weil, R., Laurent-Winter, C., and Israel, A. Regulation of IκBβ degradation. Similarities to and differences from IκBα. J. Biol. Chem., 272: 9942-9949, 1997.
21. Whiteside, S. T., Epinat, J. C., Rice, N. R., and Israel, A. IκBε, a novel member of the IκB family, controls RelA and cRel NF-κB activity. EMBO J., 16: 1413-1426, 1997. (Pubitemid 27136106)
22. Karin, M. How NF-κB is activated: the role of the IκB kinase (IKK) complex. Oncogene, 18: 6867-6874, 1999.
23. Muraki, J., Addonizio, J. C., Choudhury, M. S., Fischer, J., Eshghi, M., Davidian, M. M., Shapiro, L. R., Wilmot, P. L., Nagamatsu, G. R., and Chiao, J. W. Establishment of new human prostatic cancer cell line (JCA-1). Urology, 36: 79-84, 1990. (Pubitemid 20223256)
24. Rokhlin, O. W., Glover, R. A., and Cohen, M. B. Fas-mediated apoptosis in human prostatic carcinoma cell lines occurs via activation of caspase-8 and caspase-7. Cancer Res., 58: 5870-5875, 1998. (Pubitemid 29006431)
25. Lyakh, L. A., Koski, G. K., Telford, W., Gress, R. E., Cohen, P. A., and Rice, N. R. Bacterial lipopolysaccharide, TNF-α, and calcium ionophore under serum-free conditions promote rapid dendritic cell-like differentiation in CD14+ monocytes through distinct pathways that activate NK-κB. J. Immunol., 165: 3647-3655, 2000. (Pubitemid 32057269)
26. Gasparian, A. V., Avens, H. J., Slaga, T. J., and Budunova, I. V. Analysis of constitutive and induced NF-κB complexes in prostate carcinoma cell lines. Proceed. Am. Assoc. Cancer Res., 21: 78, 2000.
27. Kim, I. Y., and Stadtman, T. C. Inhibition of NF-κB DNA binding and nitric oxide induction in human T cells and lung adenocarcinoma cells by selenite treatment. Proc. Natl. Acad. Sci. USA, 94: 12904-12907, 1997. (Pubitemid 27518449)
28. Gasparian, A. V., Yao, Y. J., Kowalczyk, D. M., Slaga, T. J., and Budunova, I. V. Mechanisms of constitutive NF-κB activation in prostate carcinoma cells. J. Cell Sci., 115: 141-151, 2002. (Pubitemid 34105537)
29. Wang, Z., Jiang, C., Ganther, H., and Lu, J. Antimitogenic and proapoptotic activities of methylseleninic acid in vascular endothelial cells and associated effects on PI3K-AKT, ERK, JNK and p38 MAPK signaling. Cancer Res., 61: 7171-7178, 2001. (Pubitemid 32946511)
30. Makropoulos, V., Bruning, T., and Schulze-Osthoff, K. Selenium-mediated inhibition of transcription factor NF-κB and HIV-1 LTR promoter activity. Arch. Toxicol., 70: 277-283, 1996.
31. Mercurio, S. D., and Combs, G. F., Jr. Selenium-dependent glutathione peroxidase inhibitors increase toxicity of prooxidant compounds in chicks. J. Nutr., 116: 1726-1734, 1986. (Pubitemid 17177183)
32. Gladyshev, V. N., Krause, M., Xu, X. M., Korotkov, K. V., Kryukov, G. V., Sun, Q. A., Lee, B. J., Wootton, J. C., and Hatfield, D. L. Selenocysteine-containing thioredoxin reductase in C. elegans. Biochem. Biophys. Res. Commun., 259: 244-249, 1999. (Pubitemid 29281217)
33. Bours, V., Azarenko, V., Dejardin, E., and Siebenlist, U. Human RelB (I-Rel) functions as a κB site-dependent transactivating member of the family of Rel-related proteins. Oncogene, 9: 1699-1702, 1994. (Pubitemid 24163397)
34. Dejardin, E., Deregowski, V., Chapelier, M., Jacobs, N., Gielen, J., Merville, M. P., and Bours, V. Regulation of NF-κB activity by IκB-related proteins in adenocarcinoma cells. Oncogene, 18: 2567-2577, 1999. (Pubitemid 29216679)
35. Rayet, B., and Gelinas, C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene, 18: 6938-6947, 1999.
36. Sovak, M. A., Bellas, R. E., Kim, D. W., Zanieski, G. J., Rogers, A. E., Traish, A. M., and Sonenshein, G. E. Aberrant nuclear factor-κB/Rel expression and the pathogenesis of breast cancer. J. Clin. Investig., 100: 2952-2960, 1997. (Pubitemid 28022831)
37. Visconti, R., Cerutti, J., Battista, S., Fedele, M., Trapasso, F., Zeki, K., Miano, M. P., de Nigris, F., Casalino, L., Curcio, F., Santoro, M., and Fusco, A. Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFκB p65 protein expression. Oncogene, 15: 1987-1994, 1997.
38. Wang, C. Y., Cusack, J. C., Jr., Liu, R., and Baldwin, A. S., Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat. Med., 5: 412-417, 1999. (Pubitemid 29180579)
39. Huang, S., Pettaway, C. A., Uehara, H., Bucana, C. D., and Fidler, I. J. Blockade of NF-κB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene, 20: 4188-4197, 2001. (Pubitemid 32762193)
40. Duffey, D. C., Chen, Z., Dong, G., Ondrey, F. G., Wolf, J. S., Brown, K., Siebenlist, U., and Van Waes, C. Expression of a dominant-negative mutant inhibitor-κBα of nuclear factor-κB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. Cancer Res., 59: 3468-3474, 1999. (Pubitemid 29334510)
41. Barkett, M., and Gilmore, T. D. Control of apoptosis by Rel/NF-κB transcription factors. Oncogene, 18: 6910-6924, 1999.
42. Joyce, D., Albanese, C., Steer, J., Fu, M., Bouzahzah, B., and Pestell, R. G. NF-κB and cell-cycle regulation: the cyclin connection. Cytokine Growth Factor Rev., 12: 73-90, 2001.
43. Guttridge, D. C., Albanese, C., Reuther, J. Y., Pestell, R. G., and Baldwin, A. S., Jr. NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol. Cell. Biol., 19: 5785-5799, 1999. (Pubitemid 29339933)
44. Huang, Y., Ohtani, K., Iwanaga, R., Matsumura, Y., and Nakamura, M. Direct trans-activation of the human cyclin D2 gene by the oncogene product Tax of human T-cell leukemia virus type I. Oncogene, 20: 1094-1102, 2001. (Pubitemid 32238858)
45. Menter, D. G., Sabichi, A. L., and Lippman, S. M. Selenium effects on prostate cell growth. Cancer Epidemiol. Biomark. Prev., 9: 1171-1182, 2000.
46. Epinat, J. C., and Gilmore, T. D. Diverse agents act at multiple levels to inhibit the Rel/NF-κB signal transduction pathway. Oncogene, 18: 6896-6909, 1999.
47. Holmes-McNary, M., and Baldwin, A. S., Jr. Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IκB kinase. Cancer Res., 60: 3477-3483, 2000. (Pubitemid 30482167)